Summary -The Limulus amoebocyte lysate (LAL) test has replaced about 80% of the use of the rabbit pyrogen test. Ideally, human-based in vitro tests are needed, to replace the remaining use of the rabbit test and the use of the LAL test. The progress of an EU-funded project is described, in which a number of in vitro tests based on the human fever reaction are passing through a prevalidation study on the way to evaluation in a formal validation study.
Parenteral drugs have been in routine clinical use for about 100 years. During this time, the problem of pyrogenic batches of these drugs was recognised, and was finally controlled by the introduction of the rabbit pyrogen test, which has been a standardised test in all the pharmacopoeias for about 60 years. Literally millions of rabbits have been consumed per year to ensure the safety of drugs to be injected. The development of the Limulus amoebocyte lysate (LAL) test, also known as the bacterial endotoxin test (BET), and its stepwise introduction into pharmacopoeias during the last 25 years, has led to the replacement of about 80% of the animal testing by this in vitro alternative. Nevertheless, the annual consumption of rabbits for pyrogen testing worldwide still stands at about 400,000 animals per year. The LAL, despite all its success and the broadening of applications it enabled, has inherent limitations: it is restricted to the detection of endotoxins from Gram-negative bacteria, missing all Gram-positive and fungal pyrogens; it is based on the defence system of an arthropod, and does not necessarily reflect the mammalian response; and it is disturbed by components, such as serum proteins, which still permit pyrogen detection by the human immune system.
The field of applications for pyrogen testing is expanding and becoming more diverse due to innovative high-tech products such as medical devices (including, implants, medical plastics materials and dialysis machines), cellular therapies, and speciesspecific agents (for example, recombinant proteins).
Following the discovery about 20 years ago of the basis of the human fever reaction -i.e. the involvement of the blood monocyte and the tissue macrophages derived from this cell, which respond to exogenous pyrogens by the release of fever mediators such as interleukin-1 (IL-1) -it was suggested that this reaction could be exploited in a human in vitro pyrogen test. A number of tests have since been suggested, which are based on either isolated blood leucocytes, permanent monocytic cell lines or human whole-blood incubation.
The overall aim of the EU project is to develop, evaluate and validate methods based on the human fever reaction, to replace the rabbit pyrogen test and complement the Limulus assay. The network brings together the most prominent test systems that have been developed within recent years in Europe, for transnational comparison and the subsequent validation of the most promising models. This pre-competitive development should encourage further applications and exploitations for new fields of pyrogen testing, such as cellular therapies, medical devices and pyrogen pollution control in the workplace. A method for introduction into the European Pharmacopoeia will be developed as a replacement for the rabbit pyrogen test for end-product control.
The project first meeting was held in Konstanz, in conjunction with an ECVAM workshop on advanced pyrogen testing. Eight of the ten partners were able to join this workshop, with a number of additional experts from various Member States, European institutions, i.e. the European Pharmacopoeia and ECVAM, as well as a representative from the US Food and Drug Administration. This workshop resulted in a report published in ATLA (1). The overall discussion and this document serves as an additional guideline for the project. Furthermore, the workshop resulted in the establishment of closer relations between the partners in the project.
Test development has been completed for all the models included in the study, i.e. the purpose, need and derivation of each test have been defined. Each method has been published, and transferred to at least three partner laboratories. The transfer was documented, and problems that arose were recorded. Standard Operating Procedures (SOPs) were refined where appropriate. In general, the implementation of the tests did not represent a major problem. A structured exchange programme was agreed on, with formal exchange of the tests with their respective final SOP: first, a pre-phase transfer of the method from the developing laboratory to one expert laboratory and to a non-expert laboratory took place. When being trained in the expert laboratory, the recipients had to critically check the SOP, correct it and implement any comments.
One SOP was reviewed in great detail by the ECVAM team. A practical review was carried out at the developing laboratory by following the operator in the performance of the test, and by commenting on the SOP. This intensive practical SOP review was carried out to set the standard for the time when all SOPs would be practically reviewed during the first stage of the prevalidation, i.e. SOP optimisation (2) . In this way, ECVAM could provide the necessary guidance to increase the chances of successfully moving the tests through the prevalidation process, ultimately to achieve GLP compliance and the ability to participate in a blind-coded, international ECVAM validation study according to ECVAM's validation principles (2-7). The practical review was dealt with in different phases: 1) a GLP review of the SOP was performed on the version with which the developing laboratory was comfortable; 2) ECVAM forwarded comments on this procedure to the developer; 3) the ECVAM team reviewed the SOP practically; 4) during the visit, after following the experimental work, the SOP was updated instantly by a joint effort between ECVAM and the developer; and 5) a final fine-tuning of the SOPs provided an improved version which could be used in stage 2 of the prevalidation (SOP transfer).
The practical SOP revision exercise has revealed that this step is essential for SOP optimisation, because it greatly facilitates the prevalidation SOP transfer phase. Therefore, it is recommended that this should be done for all the other SOPs which are involved in the prevalidation process. Ideally, the review should be carried out at the developing laboratory. Because of the labour intensiveness of such a procedure, alternatively, a workshop could be held, at which all parties involved would be present.
It is of critical importance to involve the laboratory staff who actually perform the assay.
For all the models, an analysis procedure was defined, which clearly stated the derivation and expression of the test result from the endpoint measured, for example, a qualitative result ("the sample contains pyrogens") or a quantitative result ("the sample contains pyrogens equivalent to xIU of a reference endotoxin"). The prediction model makes a statement about the predictive in vivo result, i.e. whether the sample would fail the rabbit pyrogen test.
As a first approach, the results were compared with a spike of 0.5 endotoxin units/ml, which was calculated to be the fever threshold of the most sensitive rabbit. Starting with descriptive approaches, such as correlation coefficients and cluster analysis, prediction methods such as contingency/concordance tables and discrimination analysis will be employed to define thresholds or a more-complex prediction model at later stages of the project. This procedure will follow the recommendations of the ECVAM Biostatistics Task Force (8) , and the methodology developed by Dr Bernhard Schneider, Hannover (9) .
The project is progressing according to the Technical Annex for the EU contract. In the evaluation phase, all the laboratories were able to carry out the tests with similar limits of detection, and with overall good reproducibility (coefficient of variation below 20%). All the tests have been optimised and appear to be suitable for inclusion in the ongoing validation study. They are at least capable of detecting 0.5 endotoxin units, and delivering quantifiable results, and all the tests reacted to Grampositive lipoteichoic acid, which was negative in the LAL. This promises to close a safety gap in the endproduct control of parenterals.
The group is confident that the overall result will be a replacement for the rabbit pyrogen test. Work carried out so far indicates that the planned selection of the most promising tests will have to be postponed until later stages of the project or even omitted, as all the methods have their individual merits, and deserve intense optimisation and comparison. Currently, a blinded set of samples are being tested in phase 3 of the prevalidation study. The final validation phase will begin in September 2002, and the results are expected to be available by the end of the year.
The interest from both the regulatory authorities and industry in the project is high, as indicated by the various contributions from outside the consortium. The formal involvement of the European Pharmacopoeia, who hosted a meeting in Strasbourg in January 2001, represents a major step toward formal approval of the results of the project. The European Pharmacopoeia has already installed an International Expert Panel to draft a General Method for an in vitro pyrogen test based on the human fever reaction.
